Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universita Degli Studi Di Roma Tor Vergata |
| Country | Italy |
| Start Date | Jan 01, 2025 |
| End Date | Dec 31, 2029 |
| Duration | 1,825 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 101165168 |
WHY: The heterogeneity of tumors often makes their diagnosis and treatment a very hard task.
A single tumor can have many different diagnostically-relevant molecular markers which can also be used to monitor the efficacy of treatment.
Innovative, simple, cost-effective, and quantitative analytical tools for diagnostic and therapeutic applications are urgently needed to ensure rapid and appropriate patient care.WHAT: CO-TRANS-NET project addresses this need by developing synthetic nucleic acid units that can respond to a wide range of tumor biomarkers and can provide innovative tools for biosensing and therapeutics through cell-free in-vitro transcription.HOW: The ground-breaking idea of CO-TRANS-NET is to harness the high programmability of synthetic nucleic acids together with the high sensitivity and versatility of cell-free systems to develop co-transcriptional networks that, in one pot, through nature-inspired recognition mechanisms, can respond to a variety of targets including proteins, small molecules and antibodies and trigger in-vitro transcription of functional RNA.
The transcribed RNA can provide a measurable signal or produce a therapeutic drug.
CO-TRANS-NET aims to develop single theranostic nanodevices in which cancer diagnosis and theraphy can be simultaneously achieved- This goes beyond the state of the art and represents a breakthrough in the field of diagnostics, biosensing, synthetic biology and nucleic acid-based therapeutics.
Universita Degli Studi Di Roma Tor Vergata
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant